Leveraging its expertise in colloidal gold-based nanomedicines, CytImmune has also developed a patented, semi-synthetic in vitro immune system capable of producing fully-human monoclonal antibody (mAb) therapeutics. The Company’s ability to produce fully human mAbs provides an additional pathway to develop proprietary anti-cancer therapeutics using its platform technology to create a separate class of nanomedicines.
CytImmune has developed a method to generate fully human monoclonal antibodies (mAbs) using lymphocytes from normal donors. The technology uses the properties of gold nanoparticles to create an “antigen presentation” system, which loosely mimics the natural presentation of antigens by cells. The Company has begun proof of principle studies with antibodies against multiple components of the interleukin-2 receptor to block the production of T-cells for the treatment of leukemia and lymphoma.